Amid reporting a loss of about $2.0 million for the quarter, Celcuity also said that it had completed the development of its second test, for breast cancer, based on the CELx platform.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The flow cytometry-based HIT Confirm test is a first-in-class functional test that provides results in 30 minutes, according to Emosis.
The firm's CEO said that by the end of the year, Celcuity will complete development of new cell-signaling function tests for breast and two other cancer types.
In the third quarter, the firm inked a new lease agreement and completed its initial public offering, receiving aggregate net proceeds of $23.3 million.
The firm had been notified by the exchange in August that it failed to meet a listing requirement calling for a minimum $1 bid price on its stock.
The cell-based diagnostics firm sold a total of 2.76 million shares, including 360,000 shares to the offering's underwriter.
The company is developing a test based on computational quantitation of a subtype cells called MDSCs, which play a role in the tumor microenvironment.
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.